Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

IntroductionThe first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under syste...

Full description

Bibliographic Details
Main Authors: Anna Soria, Mariona Calvo, Meritxell Casas, Zara Vidales, Sergio Muñoz-Martínez, Victor Sapena, Marc Puigvehi, Lidia Canillas, Raquel Guardeño, Adolfo Gallego, Beatriz Mínguez, Diana Horta, Ariadna Clos, Silvia Montoliu, Mercè Roget, Maria Reig, Mercedes Vergara
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
sorafenib
elderly patients
hepatocellular carcinoma
overall survival
safety
outcome
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.829483/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.829483/full

Similar Items